99 results about "Traumatic Stress Disorders" patented technology

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

A method, computer-readable media, and system associated with psychiatric and physiologic monitoring of a patient having PTSD or anxiety-related mental health conditions are provided. For example, data associated with a survey or questionnaire that was provided to a patient is received. A score may be determined from the data associated with the survey or questionnaire. A time-series is formed using heart-rate measurements detected by a sensor. Fractal properties, such as a Hurst exponent, may be calculated for the time-series. The score may be contextually matched to a set of reference scores. Further, the contextual matching may be used to determine a range of normative HRV values for determining whether a value associated with the patient is within the range. If the value associated with the patient is not within the range, a notification may be provided.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

The invention discloses an application of simvastatin in preparation of a medicine for treating post-traumatic stress disorder. According to the invention, a post-traumatic stress disorder model is firstly constructed, and a result shows that in post-traumatic stress disorder model animals, obvious core behavior characteristics such as fear memory overconsolidation and anxiety behavior enhancement are shown. When simvastatin is used for intervention treatment, the fear memory fading ability of the model animal is obviously improved, and the anxiety behavior is obviously relieved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in a simvastatin treatment group is remarkably shortened, the standing time and distance proportion of an open arm of an elevated cross maze are remarkably increased, the total movement distance of an open field experiment is remarkably increased, and simvastatin can effectively relieve fear memory disorder and anxiety behaviors of post-traumatic stress disorder model animals.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The application provides a traditional Chinese medicine composition for preventing post-traumatic stress disorder and a preparation method thereof. The traditional Chinese medicine composition for preventing post-traumatic stress disorder comprises the following raw materials in parts by weight: 10-20 parts of ginseng and 10-20 parts of rhizoma polygonati, and in addition, 15-25 parts of mulberry, 15-25 parts of hawthorn and 5-15 parts of raphanus sativus. The traditional Chinese medicine composition is reasonably matched, has the effects of nourishing heart and soothing nerves, benefiting qi and nourishing blood, invigorating spleen and benefiting stomach and can well play a role in preventing post-traumatic stress disorder.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity / weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory / autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT2AR.

This application discloses the use of ritonavir or its derivatives in the preparation of medicaments for treating mental disorders. This application also discloses the discovery of mice (AtLAS) with difficulty in extinction of fear memories. ‑ / ‑ Intraperitoneal injection of ritonavir significantly restored the rigidity rate in model mice. Further immunoblotting and co-precipitation confirmed that ritonavir could significantly block the binding of Syn2a and Syngr-3, and promote the formation of VAMP2, Syntaxin, and SNAP25 trimers, thereby promoting the normal release of presynaptic membrane vesicles in neurons and restoring the rigidity rate in mice with refractory rigidity, thus achieving the treatment of mental disorders such as post-traumatic stress disorder.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and / or one or more subcutaneous locations in the head and neck and / or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.

The invention relates to the field of medicine, psychology and psychotherapy, as well as to computer information technology. It is based on the 8-phase psychotherapy technique of F. Shapiro for treating stress and post-traumatic stress disorder in patients. The technique involves eight consecutive phases (EMDR Association (Eye Movement Desensitization and Reprocessing), https: / / emdr.ru / news / 2018 / emdr-terapiya-obzor-razvitiya-i-mekhanizmy-deystviya). The prototype of the claimed invention is the method described in 'Intelligent virtual environment for treating anxiety exploring the Eye Movement Desensitization and Reprocessing technique' (https: / / www.researchgate.net / publication / 357606075_Intelligent_virtual_environment_for_treati ng_anxiety_exploring_the_Eye_Movement_Desensitization_and_Reprocessing_technique). A disadvantage of the prototype is that artificial intelligence is used in a limited fashion merely to determine the level of anxiety and adjust the movement of the ball in accordance therewith, and to record information. Furthermore, the prototype presupposes the involvement of a therapist, albeit to a lesser extent than in the previous version. A virtual therapist interacts with patients by means of speech, and responses to questions from a real therapist, in addition to anxiety level and heart rate, must be logged by the real therapist with the aid of a keyboard during communication with patients in virtual reality. A further disadvantage of the prototype is its focus on solving a limited number of patient problems (relieving stress and PTSD), i.e. only one protocol is used, and the fact that it cannot be used without the involvement of a therapist. The prototype is unable to provide a diagnostic assessment of problematic states of a wide range of psychological problems, select a corrective protocol, monitor the effectiveness of correction, and propose additional methods of correction. The claimed invention solves the technical problem of broadening the range of negative and problematic states that can be diagnosed (not just the level of PTSD) and making it possible to select and implement the specific protocol required to correct the problem identified, as well as to assess the effectiveness of correction and to propose additional solutions, wherein all of these aims are achieved without involving a therapist. A significant defining feature of the proposed method is the possibility of identifying a problem state in an initial step and selecting a suitable software-automated protocol tailored to each identified category of problem.

This invention belongs to the field of biomedical technology, and specifically relates to a nutrient composition for the prevention and / or treatment of post-traumatic stress disorder (PTSD). This invention utilizes metabolomics technology to screen and identify metabolite changes occurring during the pathophysiological process of PTSD, and then designs a nutrient composition comprising five components: α-ketoglutarate, thiamine hydrochloride, L-serine, L-tryptophan, and L-tyrosine. Combined supplementation of these five nutrient components effectively improves anxiety-like behavior and promotes the extinction of fear memories in PTSD model mice. Furthermore, the nutrient composition of this invention exhibits extremely high safety, with side effects far lower than traditional chemically synthesized drugs, and is expected to improve long-term patient adherence.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. Pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent, or excipient are also provided. Compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. In some embodiments, compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511124000359.jpg20170

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The application discloses application of methylphenidate in preparation of a post-traumatic stress disorder (PTSD) psychotherapy enhancer. The methylphenidate is used in the introduction period of PTSD psychotherapy, and can improve the treatment effect of core symptoms of PTSD, including intrusive symptoms, avoidance symptoms, high vigilance symptoms, negative thinking and emotion. The application uses single methylphenidate to disturb patients into an unstable state, adjusts a time window for reconsolidation of trauma memory, and strengthens the decline of trauma memory and the update of healing memory in the time window. Furthermore, compared with daily medication, single medication has clinical significance of reducing the psychological burden and economic burden of patients on drug use. Therefore, the application uses single methylphenidate in the introduction period of PTSD psychotherapy.

Heteroaromatic compounds are provided which are allosteric modulators of the cannabinoid receptors and which are useful for the treatment of glaucoma, pain, neuropathic pain, post-traumatic stress disorder (PTSD), and neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases where cannabinoid receptors are involved.

This invention provides an application of the combined use of rhizoma sarcodactylis and ginsenosides in the prevention and / or treatment of neuropsychiatric disorders, relating to the field of biomedical technology. The combined use of rhizoma sarcodactylis and ginsenosides demonstrates significant effects in improving symptoms of post-traumatic stress disorder (PTSD) and depression, exhibiting a synergistic effect. It effectively alleviates invasive symptoms caused by post-traumatic stress events; reduces fear-avoidance of trauma-related stimuli in mice; effectively improves hypervigilance states such as arousal and sleep disturbances; significantly reduces anxiety levels in stressed mice; reverses stress-induced anhedonia; not only fades traumatic memories but also protects and improves normal neutral memory function; and for depression, it effectively reduces anxiety-like and depression-like behaviors in depressed model mice, overcoming the memory generalization problem that may arise from traditional treatments.

The invention discloses a non-invasive nasal terahertz wave irradiation method and application, and relates to the technical field of terahertz. The terahertz irradiation system is assembled and built, terahertz waves with a certain frequency are used, the output power of the tail end of an optical fiber is adjusted to be 10-30 mW through optical fiber coupling, and noninvasive nasal terahertz wave irradiation is carried out on animals. Under the irradiation condition, the related symptoms of the post-traumatic stress disorder animal are improved. According to the method, non-invasive nasal terahertz wave nerve regulation and control are achieved in a nasal irradiation mode, and a new method is provided for follow-up non-invasive treatment of central nervous system diseases.

Methods of treating a subject with abnormal sleep associated with rapid eye movement (REM) sleep and slowing the progression of disease to synucleinopathies and Parkinson's disease by administering to the subject a formulation comprising an effective amount of piromelatine. Methods of treating a subject having abnormal sleep associated with rapid eye movement (REM) sleep and slowing the progression of abnormal sleep to chronic post-traumatic stress disorder (PTSD) by administering to the subject a formulation comprising an effective amount of piromelatine.

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.